AmnioGraft®: Treating Ocular Conditions Like Pterygium

The Gold Standard for Pterygium Surgery

Over the years of treating Pterygium patients, Neel Desai, MD developed an effective technique for primary pterygium surgery using AmnioGraft that reduced recurrence rate and surgical time with little to no pain reported.

Fill out the contact form and download the free surgical guide.

AmnioGraft, an amniotic membrane graft, helps rapidly restore the healthy ocular surface when used during ocular surface reconstruction surgery, especially with pterygium and conjunctivochalasis (CCh) procedures. Delivering the unique therapeutic advantage of cryopreserved amniotic membrane tissue, AmnioGraft can help your patients achieve superior cosmetic outcomes and maximize longterm results.3,4,6,7

  • Expedite ocular surface recovery. Check out our FREE guide today!

  • By clicking the button below, I agree to receive marketing communications from Bio-Tissue. I am aware that I can unsubscribe at any time.

Ophthalmologists need proven outcomes.

The platform technology behind AmnioGraft® is supported by more than

Why Intervene with AmnioGraft?

Discover AmnioGraft® 

A transplantation graft used by ophthalmologists around the world to manage
ocular surface indications such as corneal ulcers, pterygium, Stevens-Johnson Syndrome, and conjunctivochalasis (CCh).

Support Accelerated Post-Op Recovery1

AmnioGraft® expedites patient recovery by reducing inflammation5,9-11 and promoting fast, regenerative healing – typically within 2-3 weeks1-7. It helps prevents disease recurrence 1,2,6-8 as demonstrated in a study of 535 patients. AmnioGraft creates a durable recurrence barrier proven to support sustained healing with ≤5.8%* recurrence after 1 year1.

Creating a Healing Environment

AmnioGraft contains the only cryopreserved amniotic membrane that is FDA-cleared and designated for anti-inflammation, anti-scarring and anti-angiogenesis. Proprietary CryoTek preservation method retains the biologic properties and structural integrity is equivalent to fresh tissue2,12.

See What Others Are Saying About AmnioGraft

Mark Milner, MD

“Dry eye disease isn’t just simply a problem with quantitative tear film, meaning a low tear volume. Dry eye can also be from an abnormal tear film where you have tears, but they’re either unhealthy, or they’re not getting to the location that they need to, and one of the classic examples is what we call ‘Conjunctivochalasis’ or Mechanical Dry Eye.”

Neel Desai, MD

 “We’ve all had the paradoxical patient that seems to have dry eye and typical ocular surface disease, but they simply don’t respond to all of the typical conventional therapies…there is a missing x-factor. And that x-factor is this Mechanical Dry Eye concept, or conjunctivochalasis.”

Cliff Salanger, MD

“Mechanical Dry Eye is rampant; it’s almost ubiquitous in individuals over the Medicare age of 65, and we have to look for it. The key is making the diagnosis. “


References

1 Rosen R. Amniotic membrane grafts to reduce pterygium recurrence. Cornea. 2017;0:1–5.
2 Cooke M, Tan EK, Mandrycky C, et al. Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. J Wound Care. 2014;23(10):465-476.
3 Kheirkhah A, Casas V, Esquenazi S, et al. New surgical approach for superior conjunctivochalasis. Cornea. 2007;26(6):685-691.
4 Kheirkhah A, Casas V, Blanco G, Li W, Hayashida Y, Chen YT, Tseng SC. Amniotic membrane transplantation with fibrin glue for conjunctivochalasis. Am J Ophthalmol. 2007;144(2):311-3.
5 Tseng S, Espana E, Kawakita T, et al. How does amniotic membrane work? The Ocular Surface. 2004; 2(3):177-187.
6 Solomon A, Pires RTF, Tseng SCG. Amniotic membrane transplantation after extensive removal of primary and recurrent pterygia. Ophthalmology. 2001;108:449-460.
7 Georgiadis NS, Terzidou CD. Epiphora caused by conjunctivochalasis: treatment with transplantation of preserved human amniotic membrane. Cornea. 2001; 20(6):619-621.
8 Desai NR, The Tissue Tuck™ Technique: Sutureless pterygium surgery with AmnioGraft reduces recurrence rate to less than 1%. Opthalmol Manag. 2015. http://www.visioncareprofessional.com/emails/omd/corneaeupdate/6/index.html. Accessed September 19, 2019.
9 Shay E, He H, Sakurai S, Tseng SC. Inhibition of angiogenesis by HC·HA, a complex of hyaluronan and the heavy chain of inter-α-inhibitor, purified from human amniotic membrane. Invest Ophthalmol Vis Sci. 2011; 52(5): 2669–2678.
10 Zhang S, He H, Day AJ, Tseng SC. Constitutive expression of inter-α-inhibitor (IαI) family proteins and tumor necrosis factor-stimulated gene-6 (TSG-6) by human amniotic membrane epithelial and stromal cells supporting formation of the heavy chain-hyaluronan (HC-HA) complex. J Biol Chem. 2012;287(15):12433-1244.
11 He H, Zhang S, Tighe S, Son J, Tseng SC. Immobilized HC-HA polarizes LPS-activated macrophages toward M2 phenotype. J Biol Chem. 2013; 288(36): 25792–25803.
12 Tan EK, Cooke M, Mandrycky C, et al. Structural and biological comparison of cryopreserved and fresh amniotic
membrane tissues. J Biomater Tissue Eng. 2014;(4):379–388.

DISCLAIMER

Bio-Tissue, Inc. will use reasonable efforts to include accurate and up-to-date information on this Website but makes no warranties or representations of any kind as to its accuracy, currency, or completeness.

The contents of this web site are protected by applicable copyright laws. No permission is granted to copy, distribute, modify, post or frame any text, graphics, video, audio, software code, or user interface design or logos.

The information contained on this website is for general information and educational purposes only, and is not intended to diagnose, treat, or cure any medical conditions. Please consult with your Physician for medical advice.

Bio-Tissue, Inc. and its affiliates furnish this allograft product without any express or implied warranties. All statements or descriptions are informational only and are not to be interpreted or implied as a warranty of the allograft product. Bio-Tissue, Inc. and its affiliates make no guarantee regarding the biological characteristics of this product. The end user shall be held responsible for determining the appropriate application and usage of this product.